- Home
- ALHC vs GPCR Comparison
ALHC vs GPCR Comparison
Compare ALHC & GPCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | ALHC | GPCR |
|---|---|---|
| Founded | 2013 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.8B | 3.9B |
| IPO Year | 2021 | 2023 |
Fundamental Metrics
Financial Performance| Metric | ALHC | GPCR |
|---|---|---|
| Price | $21.28 | $53.49 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 9 | 11 |
| Target Price | $23.00 | ★ $103.36 |
| AVG Volume (30 Days) | ★ 3.2M | 1.1M |
| Earning Date | 04-30-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 100.00 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $3,948,719,000.00 | N/A |
| Revenue This Year | $33.69 | N/A |
| Revenue Next Year | $24.74 | N/A |
| P/E Ratio | $405.00 | ★ N/A |
| Revenue Growth | ★ 46.06 | N/A |
| 52 Week Low | $11.63 | $15.80 |
| 52 Week High | $23.87 | $94.90 |
Technical Indicators
Market Signals| Indicator | ALHC | GPCR |
|---|---|---|
| Relative Strength Index (RSI) | 64.14 | 47.49 |
| Support Level | $19.93 | $17.89 |
| Resistance Level | $23.60 | $61.20 |
| Average True Range (ATR) | 0.90 | 3.52 |
| MACD | 0.46 | 1.31 |
| Stochastic Oscillator | 77.30 | 72.77 |
Price Performance
Historical ComparisonAbout ALHC Alignment Healthcare Inc.
Alignment Healthcare Inc is a next-generation, consumer-centric platform that is revolutionizing the healthcare experience for seniors through Medicare Advantage plans. These plans are marketed and sold direct-to-consumer, allowing seniors to select the manner in which customers receive healthcare coverage and services on an annual basis. The company combines a technology platform and clinical model for more effective health outcomes.
About GPCR Structure Therapeutics Inc.
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.